The authors comment on a study published within the issue which reviewed oncolytic herpes virus injection for malignant glioma. Topics covered include several caveats to consider when interpreting the data on the injection's clinical efficacy and broader clinical implementation, the strengths and limitations of the study, and work needed to better assess post-marketing efficacy and safety.